Treatment of Premalignant Conditions
Available
All slides included
Preventing multiple types of cancer through HPV vaccination
Douglas R. Lowy
National Cancer Institute, Bethesda, MD, United States
Treatment of Premalignant Conditions
Available
All slides included
Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists
Paul A. Bunn
University of Colorado Denver, Aurora, CO, United States
Treatment of Premalignant Conditions
Available
All slides included
Use of presurgical models to screen active agents for breast intraepithelial neoplasia
Andrea De Censi
E.O. Ospedali Galliera, Genova, Italy
Treatment of Premalignant Conditions
Available
All slides withheld
Cancer interception and reverse migration
Scott M. Lippman
University of Texas MD Anderson Cancer Center, Houston, TX, United States
Clinical Trial Paradigms in the Era of Novel Therapies
Available
Some slides withheld
New paradigms for early-phase clinical trials
James H. Doroshow
National Cancer Institute, Bethesda, MD, United States
Clinical Trial Paradigms in the Era of Novel Therapies
Available
All slides included
Phasing out phase III trials: How much evidence do we need if the target is clearly hit?
Jaap Verweij
Erasmus University Medical Center - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
Clinical Trial Paradigms in the Era of Novel Therapies
Available
All slides included
Development of clinical trials incorporating genomic signatures: Lessons learned
Lisa M McShane
National Cancer Institute, Bethesda, MD, United States
Clinical Trial Paradigms in the Era of Novel Therapies
Available
All slides included
Clinical trial designs for targeted therapies
John J. Crowley
Cancer Research and Biostatistics, Seattle, WA, United States
Opening Remarks and Keynote Lectures
Chairperson
Kenneth C. Anderson
Dana-Farber Cancer Institute, Boston, MA, United States
Opening Remarks and Keynote Lectures
Chairperson
James H. Doroshow
National Cancer Institute, Bethesda, MD, United States
Opening Remarks and Keynote Lectures
Chairperson
Stefan Sleijfer
Erasmus Medical Center, Rotterdam, Netherlands
Presentation given by Jean-Yves Blay
Centre Léon Bérard, Lyon, France
Opening Remarks and Keynote Lectures
Overcoming barriers to new drug development
William N. Hait
Johnson & Johnson Pharmaceutical R&D, Raritan, NJ, United States
Opening Remarks and Keynote Lectures
Genomic profiling for personalized medicine
P. Andrew Futreal
Wellcome Trust Sanger Institute, Cambridge, United Kingdom
Novel Clinical Paradigms in Personalized Medicine
Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer
José Baselga
Massachusetts General Hospital Cancer Center, Boston, MA, United States
Novel Clinical Paradigms in Personalized Medicine
Optimizing targeted treatment of EGFR mutant lung cancer
William Pao
Vanderbilt University, Nashville, TN, United States
Novel Clinical Paradigms in Personalized Medicine
Predicting response and resistance to targeted anticancer therapeutics
Levi A. Garraway
Dana-Farber Cancer Institute, Boston, MA, United States
Novel Clinical Paradigms in Personalized Medicine
The neoadjuvant model in breast cancer research: stories of success
Serena Di Cosimo
Vall d'Hebron University Hospital, Barcelona, Spain
Lessons from the BRAF-targeted Therapy of Melanoma
Available
All slides included
Changing cell fate in cancer: Lessons from melanoma
Leonard I. Zon
Harvard Medical School, Children's Hospital, Boston, MA, United States
Lessons from the BRAF-targeted Therapy of Melanoma
Permission not
granted for webcast
BRAF and RAS signaling in cancer: From biology to therapeutics
Richard M. Marais
Institute of Cancer Research, London, United Kingdom
Lessons from the BRAF-targeted Therapy of Melanoma
Permission not
granted for webcast
BRAF and MEK inhibition in melanoma
Tona M. Gilmer
GlaxoSmithKline, Research Triangle Park, NC, United States
Lessons from the BRAF-targeted Therapy of Melanoma
Available
All slides withheld
ERK pathway inhibitors in melanoma -- sensitivity and resistance
Neal Rosen
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Proffered Paper Session 1
Available
All slides included
Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Poulikos I. Poulikakos
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Proffered Paper Session 1
Available
All slides included
KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non small cell lung cancer
Sarah Bacus
Quintiles Transnational Corp., Westmont, IL, United States
Proffered Paper Session 1
Available
All slides withheld
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a Phase II clinical trial of Pertuzumab and Erlotinib
Elizabeth Punnoose
Genentech, Inc., South San Francisco, CA, United States
Proffered Paper Session 1
Available
Some slides withheld
Gene amplification of Anaplastic Lymphoma Kinase in Inflammatory Breast Cancer
Fredika M. Robertson
UT MD Anderson Cancer Ctr., Houston, TX, United States
©2001-2011 American Association for Cancer Research | 615 Chestnut St. 17th Floor, Philadelphia, PA 19106